Skip to main content
N. Barda on Muck Rack

N. Barda

As seen in: ScienceDirect
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with N.

Contact N., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection

|
By N. Dagan, N. Barda, E. Kepten, O. Miron
| ScienceDirect Verified
Under a Creative Commons license open access Keywords SARS-CoV-2 Breakthrough infection Neutralizing activity Anti-spike antibody Anti-RBD antibody Humoral immunity 1. Introduction Vaccine-induced immunity played a crucial role in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the epidemics of the wild-type (WT) and Delta (B.1.617.2) strains [1], [2].
Open in Who Shared Issue with article?

Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis

|
By N. Barda, N. Dagan, Y. Ben-Shlomo, A. Husby
| ScienceDirect Verified
Referred to by Journal of the American College of Cardiology, Volume 80, Issue 24, 13 December 2022, Pages 2266-2268 Peter P. Liu, Tahir S.
Open in Who Shared Issue with article?

Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy)

|
By N. Dagan, N. Barda, E. Kepten, O. Miron
| ScienceDirect Verified
4. Discussion This is one of the first studies estimating the effectiveness of both Comirnaty and Vaxzevria in preventing SARS-CoV-2 infection in a large resident population in Italy. We were able to provide weekly estimates of Comirnaty effectiveness up to three months from the first dose administration.
Open in Who Shared Issue with article?
See all 3 articles